Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bortezomib + Ibrutinib|
Velcade (bortezomib) inhibits cellular proteasome activity, thereby altering multiple signaling pathways and induces cytotoxicity and apoptosis. Velcade (bortezomib) also inactivates the NF-kB pathway in various cancers (PMID: 20530581). Velcade (bortezomib) is FDA approved for the treatment of relapsed and refractory mantle cell lymphoma and refractory multiple myeloma (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Ibrutinib||Imbruvica||PCI-32765||BTK inhibitor 32 EGFR Inhibitor (Pan) 55 HER2 Inhibitor 36||Imbruvica (ibrutinib) is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which promotes apoptosis and inhibits B-cell mediated signaling pathways, and has additional activity against ERBB2 (HER2) and EGFR (PMID: 20615965, PMID: 21422473, PMID: 27678331). Imbruvica (Ibrutinib) is FDA approved for use in patients with mantle cell lymphoma, CLL/SLL and CLL/SLL with del 17p, Waldenstroem’s macroglobulinemia, marginal zone lymphoma, and in combination with Rituxan (rituximab) for untreated CLL/SLL (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03617484||Phase II||Bortezomib + Ibrutinib||Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma||Withdrawn||USA||0|